Metabolic Effect at Six and Twelve Months of Cyproterone Acetate (2 mg) Combined with Ethinyl Estradiol (35 µg) in 31 Patients

In a study from 1990 involving 31 female patients with moderate clinical hyperandrogenism, the combination of 2 mg cyproterone acetate and 35 µg ethinyl estradiol was administered for one year to assess its metabolic effects. The study found no significant changes in weight, body mass index, glucose tolerance, or insulinemia after 12 months. However, there was an observed increase in triglycerides, total cholesterol, and HDL cholesterol levels, while the LDL + VLDL/HDL and A₁/B apoprotein ratios remained unchanged. The study concluded that the combination therapy does not adversely affect glucose tolerance and has an estrogenic effect on lipid parameters. The metabolic effects, particularly on lipid profiles, were attributed mainly to the estrogen component of the therapy.